Benserazide (hydrochloride)

Benserazide hydrochloride (Serazide) is an aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase inhibitor. Benserazide hydrochloride is also a PKM2 inhibitor. Benserazide hydrochloride directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up-regulation of OXPHOS. Benserazide hydrochloride can be used for the study of Parkinson's disease and melanoma[1][2][3].

Product Specifications

CAS Number

[14919-77-8]

Product Name Alternative

Ro 4-4602 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Pyruvate Kinase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Benserazide-hydrochloride.html

Purity

99.68

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL

Smiles

NC(CO)C(NNCC1=CC=C(O)C(O)=C1O)=O.Cl

Molecular Formula

C10H16ClN3O5

Molecular Weight

293.70

Precautions

H315, H319, H335

References & Citations

[1]Shen H, et al. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J Exp Med. 2003 Mar;199 (3) :149-59.|[2]Chandel TI, et al. A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin. Biochim Biophys Acta Proteins Proteom. 2019 Mar;1867 (3) :275-285.|[3]Zhou Y, et al. Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment. Int J Cancer. 2020 Jul 1;147 (1) :139-151.